continues to support multinational clinical studies. The current program focuses primarily on patients presenting with Multiple Sclerosis (MS). These open trials do not use placebos. The purpose of these investigations is to evaluate a new, once a day, sublingual homeopathic preparation (sprayed under the tongue) that replaces injectable dosage formats currently used by most MS patients. Patients commit to the treatment/study for a minimum of a Half-Year. Esperanza Peptide offers three treatment prices (a half-year, full-year and 18-month price). First, we offer subsidised, full year and 18-month treatments, that costs the participating patient £5,450 (UK) for full-year and £7,450 for 18-months, $12,500 (USA) for full-year and $17,000 for 18-months, or €7,700 (Europe) for full year, €10,000 for 18-months and equivalent currency in other countries. Second, we offer a 6 month "half-year treatment" for those that want to try the Esperanza NeuroPeptide treatment before fully committing to the full-year or 18-month treatment. The half-year treatment prices are £3,750 (UK), $6,250 (USA) and €5,250 (Europe) this "half-year treatment" unlike the full-year and 18-month treatment price is not subsidisedor. The costs include all of the clinical assessments, dosing analysis and consultations with our Practitioners and clinic team, as well as one year's supply of the Esperanza Peptide Homeopathic Sublingual Spray. NOTE: there is also a Half-Year period available For information and comparison between the Full-Year or 18-Month treatment price and the Half-Year treatment price click here.

Once accepted into the open multinational treatment program, patients are scheduled for evaluation at one of our many clinics worldwide (for list of available clinics click here). Patients are tested and evaluated for upper body function, lower body function, balance, speech and cognitive function. The initial testing, evaluation, dosing and retesting takes approximately three to four hours. Some of the tests and evaluations are video taped. Patients are monitored, re-evaluated and re-tested at various points throughout the treatment period for protocols at the various clinics worldwide click here. Each patient is responsible for their own transportation, to and from the clinics. Families, friends and significant others are welcome and encouraged to accompany the patient to the clinics.

Many patients regain function and experience fewer and less severe MS exacerbations. We do not believe this treatment is a cure. It is much like insulin is to a diabetic. It only works if it is taken daily. There is often measurable improvement in speech, pain, strength, balance and motor function in the first few days. Patients often continue to improve and usually plateau between year one and year three (every patient is unique and as such results and timeframes vary). The goal of these treatment studies is to statistically evaluate the changes that provide MS patients with an improved quality of life.

To read a more definitive report on expectations and possible results after your Esperanza NeuroPeptide treatment click here.

The Sublingual Homeopathic spray (Esperanza Homeopathic NeuroPeptide) contains a peptide (71 amino acid chain) at a concentration of 10ug/ml. The daily dose is 6ug. The sublingual preparation is non-toxic, and in studies to date, these preparations have exhibited no adverse side effects.

IF YOU ARE INTERESTED IN PROGRESSING AND GETTING FURTHER INFORMATION CLICK HERE.

IF YOU WISH TO BOOK A CLINIC APPOINTMENT FOR TREATMENT AT A CLINIC NEAR YOU CLICK HERE.

IF YOU ARE INTERESTED IN VIEWING AVAILABLE CLINICS WORLDWIDE CLICK HERE.

IF YOU WISH TO COMPARE A FULL-YEAR OR 18-MONTH TREATMENT AS OPPOSED TO THE HALF-YEAR TREATMENT PRICES CLICK HERE.

CLINICAL TRIAL PROGRAM

Esperanza Peptide plans to conduct ongoing trials with both humans and animals. In humans, the first application of these unique peptides will be the treatment of Multiple Sclerosis (MS).

It is believed that our unique peptide product could supersede interferon-based treatments whose sales currently generate over $2 billion per annum. With over 3 million MS patients globally requiring medication specifically for their condition, our unique peptide supplement efficacy and cost will guarantee significant market penetration.

CLINICAL TRIAL FUNDING

To date, funds have been spent on the evaluation of the new and cutting edge Esperanza Homeopathic NeuroPeptide sublingual spray into preliminary clinical trials. We are in the process of raising $15 million in order to continue and expand these trials.

We expect much of this funding will come via donations from various philanthropic organisations, corporate and private donations. Any interested individual, group, association or organisation can contact us by filling out our contact information form.

Our focus is to proceed to human clinical trials in the U.K. and Canada as soon as $10 million is available. This sum is expected to cover the initial cost of the clinical evaluation and chronic toxicity / reproductive studies required for approval.

Once phase two trials have been successful, we will then be in a position to bring a proven and fully documented drug to the attention of major pharmaceutical companies (known as "Big Pharma") in a format that lets them purchase rights. Such a licensing agreement with "Big Pharma is expected to bring significant amounts of funding to help us move forward with our various projects. This is an exciting time for Esperanza Peptide as we embark upon partnership with "Big Pharma" and the expansion of our pipeline of drug products and remedies to combat diseases and serious medical conditions worldwide!

Thank you for studying this information; if we can be of any further assistance, please do not hesitate to contact us.